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Sex Med RIntroduction: Information about the possible effects of cutaneous immune-mediated diseases (cIMDs) on male
sexual function and reproduction is scarce. Factors known to impair sexual health and reproduction, such as
inflammation, medication use, and hypogonadism, can be present in a significant proportion of male patients
with cIMD.
Objectives: To systematically review the literature for the influence of paternal cIMD on many aspects of male
sexual and reproductive health, such as sexual function, reproductive hormones, fertility, and pregnancy and
offspring outcomes.
Methods: A systematic literature search was performed. The searches combined keywords regarding male sexual
function and fertility, pregnancy outcomes, and offspring's health with a list of cIMDs.
Results: The majority of the identified studies included patients with psoriasis (22 of 27), and sexual function was
themost commonoutcome of interest (20 of 27). For patients diagnosedwith psoriasis, the prevalence ofmale sexual
dysfunction reported in these studies ranged from 34 to 81%.Hypogonadism in patients with psoriasis was reported
in 2 of 3 studies. Sperm analysis abnormalities in patients with psoriasis were reported in 3 of 4 studies. No in-
formation about the effect of paternal disease on pregnancy and offspring outcomes was identified.
Conclusions: Disease activity in psoriasis might play an important role in the development of sexual
dysfunction, hypogonadism, and abnormal sperm quality. For the other cIMD included in this review, there is
insufficient information regarding male sexual and reproductive health to draw firm conclusions. More research is
needed to understand the association between cIMD and impaired male sexual and reproductive health. Perez-
Garcia LF, Dolhain R, te Winkel B, et al. Male Sexual Health and Reproduction in Cutaneous Immune-
Mediated Diseases: A Systematic Review. Sex Med Rev 2020;XX:XXXeXXX.
Copyright  2020, The Authors. Published by Elsevier Inc. on behalf of the International Society for Sexual Medicine.
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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Sexual and reproductive health (SRH) is defined as a state of
complete physical, mental, and social well-being in all matters
relating to the reproductive system, and every individual shoulday 18, 2020. Accepted July 17, 2020.
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2 Perez-Garcia et al40 years of age2 and that the fertility rate in men younger than
30 years of age is decreasing worldwide.3 In addition, poor semen
quality is now considered as a biomarker of poor general health
and it has been associated with an increased mortality rate.4
Cardiovascular disease, obesity, smoking, depression, and
anxiety are among the “classic” risk factors that are associated
with this increased rate of SRH problems. In addition, an asso-
ciation between inflammation and SD has been described.
Recently, a systematic review concluded that evidence suggests a
role for the immune system in the generation of an inflammatory
environment that contributes to vascular impairments and the
development of erectile dysfunction (ED).5 Inflammation of the
reproductive tract is also considered as a significant cause of male
factor infertility.6
Immune-mediated diseases (IMDs) are characterized by dys-
regulated immune responses leading to tissue-damaging inflam-
mation and are also strongly associated with cardiovascular
disease and comorbidities such as depression and anxiety.7,8
Altogether, this evidence led us to believe that systemic
inflammation associated with IMD could also have a significant
role in the development of SD and/or infertility. We began to
test our hypothesis in the field of rheumatology, considered the
hallmark field of autoimmunity. In rheumatic diseases such as
rheumatoid arthritis or systemic lupus erythematosus, a link
between inflammation and an impaired SRH seems plausible.9
The skin, a physical barrier that protects internal systems
from foreign bodies, also participates actively as an immune
organ. Dermatologic lesions of the external genitalia are
common in men with psoriasis (30e40%) and can also be
found in men diagnosed with other cutaneous IMDs (cIMDs).
These lesions are associated with considerable physical symp-
toms and psychological distress that can directly impact male
SRH.10 Furthermore, SRH in men diagnosed with cIMD
without genital lesions can also be impaired owing to other
factors such as inflammation, medication, or associated
comorbidities.
A review article published in 2009 concluded that “SD should
be investigated and treated in patients with skin diseases.”11 A
recent meta-analysis that included data from 9 studies and
included 36,242 patients with psoriasis concluded that psoriasis
was associated with an increased risk of ED.12 Nonetheless,
except for psoriasis, male SRH can still be considered as a
neglected topic in dermatology.
Men diagnosed with a cIMD should receive proper SRH
counseling. This information should not be limited to discussing
the possible side effects from drugs on a future pregnancy
(reproductive toxicology) but the impact that disease itself has on
SRH should also be considered.
Our objective was to systematically review the literature for the
influence of paternal cIMD on many aspects of SRH, such as
sexual function, male fertility, pregnancy outcome, and on their
offspring health outcome.MATERIALS AND METHODS
This review is part of a larger systematic review (SR) that also
included IMD from rheumatology and gastroenterology. The
complete protocol was written in accordance with the
PRISMA-P statement9 and registered in PROSPERO and is
available in https://www.crd.york.ac.uk/prospero/display_record.
php?RecordID¼99845. The results from the rheumatology
section have been published elsewhere.9Search
A search strategy was developed by an experienced medical
librarian (W.B.) using a structured methodology.13 The searches
combined keywords regarding male sexual function and fertility,
pregnancy outcomes, and offspring's health with a list of cIMDs.
Our full search strategy is provided in Supplement 1.Information Sources
A systematic literature search was performed in the biblio-
graphic databases: Embase (via Elsevier embase.com), MED-
LINE via Ovid, Cochrane Central Register of Trials, and Web of
Science Core Collection. In addition, Google Scholar and the
clinical trial registries of Europe and the United States were
searched. We also contacted authors for further information and
included references from the primary search publications, in case
these were missed in our search. The databases were searched
from inception until February 28, 2019.Eligibility Criteria
The literature search was limited to the English language and
human subjects. Case-control studies, cohort studies, cross-
sectional studies, case reports, and case series were included.
Publications without original data, such as reviews, were excluded.
In the case of studies reporting pregnancy and offspring out-
comes, publications were included if the diagnosis of the IMD
took place before conception. In case of studies just reporting
fertility parameters (ie, semen analysis, SD), we included publi-
cations were the diagnosis was taken into consideration. No re-
strictions were made regarding the comparison groups. The
outcome data should include at least one of the following out-
comes: sexual function, reproductive hormones, fertility, preg-
nancy outcomes, or offspring outcomes.Study Selection
All articles were imported to EndNote X9. After removal of
duplicates, 2 reviewers (L.P. and J.C.) independently and blindly
screened titles, abstracts, and full text of the records for eligibility.
Disagreements were resolved by consensus with the help of a
third reviewer (R.D.).Data Collection Process
One reviewer (L.P.) extracted relevant information for each
studied outcome from the included studies.Sex Med Rev 2020;-:1e11
Table 1. Description of characteristics and key findings of studies regarding sexual function
Article Country
Number of
participants
SD or ED
prevalence
Association
with
psoriasis
Association with
depression
Association
with disease
activity
Association
with other factors
Psoriasis
Tasliyurt et al16 Turkey 37 81.08% (ED) NA þ (Independent
risk factor for
ED)
þ Significant:
Age
Smoking
Cabete17 Portugal 135 61.5% (ED) þ NA NA Significant:
Age
Height
Diabetes
Ji S18 China 191 52.9% (ED) - þ NA Significant:
Hypertension
Hyperlipidemia
Age
Molina-Leyva19 Spain 40 53.7% (SD) þ þ þ Significant:
Age
Anxiety
Molina-Leyva20 Spain 79 41.8% (SD) - þ - Significant:
Age
Smoking
Turel Ermertcan21 Turkey 39 NA þ - - NA
Bardazzi22 Italy 120 51.6% (ED) þ NA þ Not significant:
Diabetes Mellitus,
smoking,
hypertension
Wojciechowska-
Zdrojowy23
Poland 76 43.8% (ED) NA NA þ Significant:
Age
Not significant:
Cardiovascular
diseases
Diabetes
Significant:
Genitourinary
diseases
Duration of psoriasis
Goulding24 United
Kingdom
92 58% (ED) - NA NA Significant:
Age
Hypertension
Egeberg25 Denmark 26,536 12.8% (ED) þ NA þ NA
Meeuwis26 Netherlands 278 NA NA NA NA Significant:
Genital psoriasis
Sampogna27 Italy 244 34.4e67.9% NA NA þ Significant:
*4 questionnaires
were used
Age
Hidradenitis suppurativa
Alavi28 Canada 17 NA NA NA NA NA
Janse29 Netherlands 66 52% (ED) NA NA - NA
Kurek30 Germany NA NA NA NA - NA
Lichen simplex
(continued)
Sex Med Rev 2020;-:1e11
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Table 1. Continued
Article Country
Number of
participants
SD or ED
prevalence
Association
with
psoriasis
Association with
depression
Association
with disease
activity
Association
with other factors
Juan31 Taiwan 5,611 3.37% (SD) NA þ NA Significant:
*Incidence Diabetes Mellitus
Hypertension
Hyperlipidemia
Cardiovascular
disease
Anxiety
Vitiligo
Sukan32 Turkey 26 11.5% (SD) NA - NA NA
Chronic urticaria
Sukan32 Turkey 16 31.2% (SD) NA þ NA NA
Atopic dermatitis
Egeberg25 Denmark 26,536 6.7% (ED) þ NA þ NA
ED ¼ erectile dysfunction; SD ¼ sexual dysfunction.
4 Perez-Garcia et alRisk of Bias in Individual Studies
The methodological quality of the studies was assessed with
the Newcastle-Ottawa Scale, developed for case-control and
cohort studies.14 In the case of cross-sectional studies, an adapted
scale was used.15 One reviewer, L.P., assessed the quality of the
studies. Using this method, points were awarded to each publi-
cation, related to the selection of the study group, the compa-
rability of the study groups and the ascertainment of the
outcomes. The score ranges from 0 to 9, with scores >5 repre-
senting good-quality studies (scores per study are presented in
Tables 1e3).RESULTS
A total of 9,735 references were identified. After removing
2,851 duplicates, 6,884 articles were eligible for title/abstract
screening, resulting in 289 articles eligible for full-text reading. A
total of 27 articles fulfilled the inclusion criteria for cIMD (see
Figure 1 and Table 4).
Results are presented per disease (when available) and were
divided into 4 categories (sexual function, reproductive hormones,
fertility outcomes, and pregnancy and offspring outcomes).Sexual Function
Sexual function in men with cIMD was the most common
outcome found in our search, these studies represent 74% of the
total included studies in this SR (for in-depth information, see
Table 1).
The importance of this topic is illustrated by the results from a
European multicenter study where 24.9% of male patients
diagnosed with a dermatologic disease reported sexual difficulties
that were strongly associated with depression and anxiety. The
highest prevalence of sexual difficulties was found in patientsdiagnosed with hidradenitis suppurativa (HS) (66.7%), blistering
disorders (34.9%), and psoriasis (34.8%).27Psoriasis
Sexual function in psoriasis was studied in 14 studies that
included 29,410 patients with a mean age of 41.07 years.
Cross-sectional studies were the most frequent study type, and
the overall quality of these studies was graded as “good quality.”
To assess sexual function, 8 of the studies used the Interna-
tional Index of Erectile Function (IIEF). Other tools also used
were the Massachusetts General Hospital-Sexual Functioning
Questionnaire in 2 studies and the Sexual Quality of Life-Men
in 1 study. Disease activity in psoriasis was reported using the
Psoriasis Area and Severity Index (PASI) that combines the
assessment of the severity of the skin lesions and the affected
area into a single score in the range of 0 (no disease) to 72
(maximal disease).16-26,41-43
Using validated questionnaires, the prevalence of SD in pso-
riasis (including ED) ranged from 34.4% to 81%.16-25,43 When
compared with a control group, the prevalence of SD was
significantly higher in patients with psoriasis. Using the IIEF
questionnaire, the highest prevalence of ED was reported by
Tasliyurt et al.16 In their study, a prevalence of 81.08% was
found in a population of 37 patients with psoriasis (mean age:
45.19 ± 13.82 years, mean PASI: 8.25 ± 4.42) compared with
53.57% in 28 healthy men (mean age: 40.89 ± 12.91 years); this
difference was statistically significant (P ¼ .018). IIEF scores had
a significant negative correlation with age, body mass index, and
PASI scores. Depression, older age, and smoking were found to
be independent risk factors for ED.
In the study from Cabete et al,17 the prevalence of ED (IIEF-
5 score  21) was higher in patients with psoriasis than in
controls (61.5% vs 43.8%, P ¼ .001). Furthermore, it wasSex Med Rev 2020;-:1e11
Table 2. Description of characteristics and key findings of studies regarding reproductive hormones
Study
Number of cases/
controls (mean age
in years) Main findings
Study type and quality
assessment (NOS)
Psoriasis
Caldarola33 Cases: 50 (34)  Testosterone was found to be significantly decreased in
patients with psoriasis compared with the control group
(3.7 ± 1.3 vs 4.8 ± 1.2 ng/mL, respectively).
4
Controls: 50 (33.4)  Estradiol (E2) levels were higher in patients with psoriasis than
in the control group (43.8 ± 8.1 vs 29.1 ± 8.2 pg/mL).
Cross-sectional
Cemil34 Cases: 47
(55.9 ± 4.1)
 Testosterone was found to be significantly decreased in
patients with psoriasis compared with the control group
(3.9 ± 1.8 vs 5.1 ± 1.2 ng/mL, respectively).
4
Controls: NA  Estradiol (E2) levels were higher in patients with psoriasis than
in the control group (37.5 ± 17.1 vs 29.9 ± 8.7 pg/mL).
Cross-sectional
B Inverse correlation was detected between PASI and serum
level of estradiol in the psoriasis group.
Saad35 Cases: 15 (53) Observational study. Case series
Controls: 131 (NA) 15 men diagnosed with late-onset hypogonadism and psoriasis.
Treatment with testosterone undecanoate every 12 wk for up to
93 mo was associated with:
 Testosterone levels rose significantly to a eugonadal state.
 PASI declined from 19.3 ± 2.3 to 1.8 ± 0.4 (P < .0001).
 Serum C reactive protein levels decreased significantly over the
first 24 mo.
Tehranchinia36 Cases: 43
(34.1 ± 10.5)
 Testosterone levels were not statistically different between the
2 groups.
4
Controls: 42
(31.8 ± 8.9)
 Patients with psoriasis had significantly higher levels of leptin
than healthy controls (5.4 vs 2.7 ng/mL, respectively) and
lower levels of follicle-stimulating hormone (1.4 vs 2 IU/L).
Cross-sectional
B A positive correlation was reported between serum leptin
levels and disease activity.
Atopic dermatitis
Ebata37 Cases: 40 (24) Serum levels of testosterone, free testosterone, and estradiol
were significantly lower and serum levels of LH were
significantly higher in male patients with atopic dermatitis
4
Controls: 40 (24) Cross-sectional
LH ¼ luteinizing hormone; NOS ¼ Newcastle-Ottawa Scale; PASI ¼ Psoriasis Area and Severity Index.
Male Sexual Health in Dermatology 5reported that patients with psoriasis had a 2.69- and 5.3-fold
increased risk of having mild-moderate and moderate-severe
ED, respectively.
In a study from Poland, 42% of patients diagnosed with
psoriasis reported that sexual activity decreased owing to their
skin problems. ED was diagnosed in 43.8% of these patients and
its severity was correlated with age (r ¼ 0.42; P  0.001) and
with disease activity (r ¼ 0.26: P ¼ .03).23
Psoriasis was found to be an independent risk factor for ED
(odds ratio of 2.28 [95% confidence interval, 1.40e3.27]) in 1
study17 and with SD in 2 studies.18,19 No association was re-
ported in any study.21
The association between disease activity and SD was further
analyzed in 8 studies. 6 studies reported an association between
disease activity and SD.16,20,22,23,25,43 Conversely, in 2 studies,
such an association was not significant.19,21Sex Med Rev 2020;-:1e11The association between SD and depression, a known factor
that adversely affects male sexual function, was analyzed in 5
studies. An association between depression and the presence of
SD was reported in 3 studies.18-20 No association between
depression and SD in patients with psoriasis was reported in any
study.21
In a study that included 191 patients with psoriasis, Ji et al18
reported that severe depressive symptoms increased the risk of
ED. Similarly, Molina-Leyva et al19 reported that depression was
significantly associated with ED and that psoriasis per se was not
independently associated with ED.
No significant association between depression and SD was
reported in a study that included 70 men from Turkey (39
diagnosed with psoriasis and 27 healthy controls; mean age,
41.42 and 41.77 years, respectively). Interestingly, total IIEF
scores were not correlated with disease activity (PASI).21
Table 3. Description of characteristics and key findings of studies regarding fertility
Study
Number of cases/
controls (mean age
in years) Main findings
NOS quality
assessment and
study type
Psoriasis
Caldarola33 Cases: 50 (34) Total sperm count, sperm motility and percent of
spermatozoa with normal morphology were significantly
reduced in patients compared to controls.
4
Controls: 50 (33.4)  Sperm concentration, n  106/mL: 18.6 ± 11. 6 vs
62.8 ± 20.5
Cross sectional
 Total motility, %: 29.7 ± 22.7 vs 60.2 ± 10.2
 Normal morphology, %: 13.3 ± 9 vs 32.9 ± 5.5
Heppt38 Cases: 27 (37.5)  Only 4 (14.8%) patients with psoriasis showed
normozoospermia at baseline.
5
Controls: NA  85.2% of the patients had at least 1 sperm/seminal
abnormality, including 2 patients showing an azoospermia.
Cohort
 48.1% of the patients showed semen parameters indicating
a genital tract inflammation.
Grunnet39 Cases: 20 (32.4) 16 of 20 patients with psoriasis (80%) treated with topical
glucocorticoids or methotrexate had abnormal semen
parameters.
3
Controls: 10 (NA) Cross sectional
Liu40 Cases: 31 (22) Semen quality did not differ between patients and controls. 4
Controls: 14 (22) Cross sectional
NOS ¼ Newcastle-Ottawa Scale.
Records idenƟfied through 
database searching
n = 9735 
Full-text arƟcles excluded
n = 259
Title and abstract screening
n = 6884
Full-text arƟcles 
assessed for eligibility 
n = 289
Studies included in qualitaƟve 
synthesis 
n = 27
Sexual FuncƟon, reproducƟve 
hormones and ferƟlity
n = 27
Pregnancy and offspring
n = 0
Duplicates excluded
n = 2851
ArƟcles excluded 
n = 6597
Figure 1. Flow diagram for study selection.
6 Perez-Garcia et alOther relevant factors associated with SD were increasing age,
smoking, and hypertension.16-20,23,24,43 Bardazzi et al22 reported
that patients with psoriasis with ED were younger and had a
more severe form of ED in comparison with patients without
psoriasis diagnosed with ED.
Communication between patients and healthcare professionals
was analyzed in 2 studies from the United Kingdom. Only 9% of
patients with psoriasis had been previously asked by a healthcare
professional about erectile problems, whereas 68% admitted
dissatisfaction with their erectile ability and wanted more infor-
mation on this topic.24 Similarly, in a study from the
Netherlands that included 278 men diagnosed with psoriasis
(mean age, 53.9 ± 12.3 years), only 9% of patients believed that
there was sufficient attention given by their doctors to possible
sexual problems and 43% thought that healthcare professionals
should ask more frequently about possible sexual problems.26
3 studies used diagnosis codes to report the prevalence or
incidence of SD in patients with psoriasis. Data from 1,593
patients with psoriasis from the United States (aged
18e42 years) reported that a diagnosis of SD (International
Classification of Diseases-9 and International Classification of
Diseases-10 codes) was present in 7.2% of men on systemic
medications compared with 3.6% of those treated with topical or
no medications, this difference was statistically significant.41
A recent observational nationwide study from Egeberg et al25
included 1,756,679 Danish men from which 1.5% were diag-
nosed with psoriasis. The prevalence of ED was 12.8% forpatients with psoriasis compared with 8.7% in the general
population. The risk of ED was significantly increased in patients
with mild psoriasis (adjusted hazards ratio 1.14; 1.09e1.20) and
severe psoriasis (adjusted hazards ratio 1.17; 1.04e1.32).
A nationwide study from Taiwan reported a significantly
higher incidence of SD (3.03%) among 12,300 patients (median
age, 46 years) than that among age-matched controls (2.34%)
during 7 years The most prevalent SD was ED.42Sex Med Rev 2020;-:1e11
Table 4. Number of studies included per disease and topic
Disease
Total number
of studies
Sexual
function
Reproductive
hormones Fertility
Pregnancy
outcomes
Psoriasis 21 13 4 4 0
Hidradenitis
suppurativa
3 3 0 0 0
Lichen simplex 1 1 0 0 0
Vitiligo 1 1 0 0 0
Chronic urticaria 1 1 0 0 0
Atopic dermatitis 2 1 1 0 0
Male Sexual Health in Dermatology 7Hidradenitis Suppurativa
Sexual function in HS was reported in 3 studies. The IIEF
questionnaire was used in all 3 studies. The quality of these
studies was graded as “good quality.” These studies included data
on 103 patients (mean age of 41.6 years) and 42 healthy controls
(mean age of 37.8 years). The prevalence of SD in HS was re-
ported in one study. Overall, compared with healthy controls,
patients with HS reported more sexual function problems that
contribute to a lower quality of life. No association was found
between disease activity and SD.
In a cross-sectional study from Canada that included 17 pa-
tients with HS (mean age, 40.47 ± 15.49 years) and 22 healthy
age-matched control, significant differences in sexual function
assessments were identified. Patients with HS had significantly
lower Sexual Quality of Life Questionnaire for Use in Men scoresTable 5. Research recommendations
Sexual function Use standardized screening questionnaire
Case-control studies and well-designed p
studies.
Consider relevant comorbidities and pote
Collaboration with experts in the field of
Sperm quality Use standardized methods to report spe
DNA fragmentation index could provide m
considered as a secondary endpoint.
Ideally, technicians should be blinded reg
RCTs are ideal but case-control and well-d
sectional studies.
Consider disease activity, relevant medica
smoking, varicocele).
Reproductive hormones Use standardized methods to measure h
RCTs are ideal but case-control and well-d
sectional studies.
Consider disease activity, relevant comor
Pregnancy and offspring
outcomes
Collect data prospectively or report cases
 Source of the information, indication, d
paternal age.
 Regarding pregnancy/child outcome; pr
genetic testing, follow up period,
 Partner's relevant medical history.
IIEF ¼ International Index of Erectile Function; WHO ¼ World Health Oraganiz
Sex Med Rev 2020;-:1e11(P < .001) and lower IIEF scores (P ¼ .019). The authors
concluded that SD is an important contributor to impaired
quality of life in patients with HS.28
A multicenter cross-sectional study from the Netherlands
(n ¼ 66; mean age, 48.4 ± 12.3 years) reported a prevalence of
ED of 52%. No association was reported between the IIEF total
score and age of onset, duration of disease, Visual Analogue
Scale-pain score, Physician Global Assessment score, Hurley
stage, or Dermatology Life Quality index 58% of men with HS
indicated that their sexual activity declined after disease onset.29
SD was more severe in 20 patients with HS compared with 20
age-matched controls as evidenced by a lower IIEF total score
(42.6 ± 27.1 vs 62.6 ± 10.8, P ¼ .01). No significant correlation
between disease activity and the IIEF was reported.30s (IIEF).
rospective cohort studies are encouraged over cross-sectional
ntial confounders (depression, anxiety, disease activity).
sexology is encouraged.
rm quality (WHO) (primary endpoint).
ore information regarding male fertility potential and can be
arding the drug-exposure.
esigned prospective cohort studies are also encouraged over cross-
tion history, comorbidities, and potential confounders (age,
ormones.
esigned prospective cohort studies are also encouraged over cross-
bidities and potential confounders (age, medication history).
with all the relevant information. eg,
isease activity, clear description of medication use and timing
egnancy outcome, gestational age, birthweight, infant health,
ation.
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From 2000 to 2004, 5,611 male patients (mean age,
49.46 years) were diagnosed with lichen simplex in Taiwan. The
incidence of SD in this group was higher than in the general
population (3.37 vs 1.74 per 1,000 person-years). After adjusting
for age and comorbidities and using data from 22,444 age-
matched patients without lichen simplex as controls, patients
with lichen simplex had a 1.74-fold greater risk of developing
ED compared with controls (P < .001).31
Vitiligo
The prevalence of SD was not significantly different among
patients with vitiligo and healthy controls (11.5% and 16%) in 1
study from Turkey that included 26 patients and 25 healthy
controls (mean age: 35.8 and 35.9 years, respectively).32Chronic Urticaria
The prevalence of SD was not significantly different among
patients with chronic urticaria and healthy controls (31.2% and
16%) in a study that included 26 patients and 25 healthy controls
from Turkey (mean age: 38.6 and 35.9 years, respectively).32Atopic Dermatitis
In the study from Egeberg et al,25 patients diagnosed with
atopic dermatitis were also included. Interestingly, patients with
atopic dermatitis had a lower prevalence of SD than the general
population (6.7% vs 8.7%, respectively).
Reproductive Hormones
Regarding reproductive hormones, 5 studies were identified.
The quality of these studies was graded as /þ “low quality” (for
in-depth information, see Table 2).
Psoriasis
The androgenic status of 50 patients (mean age,
34 ± 8.4 years) with moderate psoriasis (PASI: 8 ± 5.5) was
investigated by Caldarola et al.33 Testosterone and sex
hormoneebinding globulin were significantly decreased in pa-
tients compared with age-matched controls (n ¼ 50). Estradiol
(E2) levels were higher in patients than controls.
An association between disease activity and low estradiol levels
was reported by Cemil et al.34 In a cross-sectional study that
included 47 patients and 20 controls (mean age: 42.87 ± 15.56
and 38.05 ± 10.14 years, respectively), serum testosterone levels
were significantly decreased in patients with psoriasis compared
with controls (392.29 ± 181.91 ng/mL and 506.91 ± 117.7 ng/
mL, respectively). Estradiol levels were significantly increased in
patients with psoriasis (37.52 ± 17.16 vs 29.9 ± 8.77), and an
inverse correlation was detected between PASI and estradiol
levels in patients with psoriasis (P < .05).
In an observational study, testosterone replacement therapy
declined PASI scores by >75% within 2 years in 15 patients
diagnosed with psoriasis and late-onset hypogonadism. This wasan observational study without controls. The possible role of
testosterone as an anti-inflammatory agent is discussed.35
Leptin, a hormone secreted by the adipose tissue that plays an
important role in reproductive function, was found to be signifi-
cantly higher in patients with psoriasis (n ¼ 43, mean age
34.09± 10.53) than that in age-matched healthy controls (n¼ 42).
This was associated with lower level of follicle-stimulating hormone
in patients compared with controls. Serum concentrations of
luteinizing hormone, total testosterone, sex hormoneebinding
globulin, and prolactin were comparable among the 2 groups. In
patients with psoriasis , disease activity and duration were signifi-
cantly correlated with log-transformed leptin levels (adjusted
R2 ¼ 0.50, F ¼ 21.87, P < .0001).36
Atopic Dermatitis
The prevalence of hypogonadism was significantly higher in
40 patients diagnosed with atopic dermatitis than that in age-
matched healthy controls. This was evidenced as patients had
lower serum levels of testosterone, free testosterone (447 ± 96 vs
593 ± 149 ng/dL and 14.6 ± 3.2 vs 20.0 ± 5.1 pg/mL, both
P < .001), and higher levels of luteinizing hormone than con-
trols (4.57 ± 1.6 vs 3.11 ± 1.2 mIU/mL, P < .001).37Fertility
Psoriasis
Regarding fertility parameters, 4 studies that reported sperm
analysis results were identified. The quality of these studies was
graded as “low quality.” Sperm analysis abnormalities in patients
with psoriasis were reported in 3 of 4 studies (1 study included
untreated patients, 1 study included patients treated with
methotrexate, and 1 study did not report treatment characteris-
tics of the patients) (for in-depth information, see Table 3).
Sperm analysis was performed in 27 untreated patients (mean
age of 37.5 years) with moderate to severe psoriasis (mean PASI
score, 11.05). Interestingly, 85.2% had at least 1 sperm/seminal
abnormality and 48.1% showed parameters indicative of genital
tract inflammation.38
Grunnet et al39 reported sperm analysis abnormalities in all 10
patients with severe psoriasis treated with topical corticosteroids
included in their study. Based on semen quality, 30% were
classified with “severely impaired fertility” (oligospermia 70%,
asthenospermia 90%) and 30% were unwillingly childless. In
contrast, sperm analysis was normal in 40% of the patients
included in their comparison group (n ¼ 10) patients with severe
psoriasis treated with methotrexate, this was statistically signifi-
cant (P ¼ .04).
In the study from Caldarola et al,33 semen analysis was also
performed. Sperm count, motility, and morphology were
significantly reduced in patients compared with controls. 50% of
patients showed 1 or more seminal parameter abnormalities.
Sperm quality was investigated in 31 young Chinese soldiers
diagnosed with psoriasis (aged 18e24 years). Compared with aSex Med Rev 2020;-:1e11
Male Sexual Health in Dermatology 9group of 14 healthy volunteers from the same population, con-
ventional sperm analysis and the measurement of sperm nuclear
DNA fragments werecomparable among the 2 groups.40Pregnancy and Offspring Outcomes
No articles were identified.DISCUSSION
Sexual Function
Patients with psoriasis, hidradenitis suppurativa, and lichen
simplex have a higher prevalence of SD. Along with the classical
risk factors, a positive correlation between psoriasis disease ac-
tivity and SD was reported in several studies. This finding invites
a discussion about how inflammation secondary to psoriasis can
contribute to the development of SD in a young population.
Although there is evidence suggesting an influence of disease
itself (via inflammation) in the development of SD, we were not
able to conclude whether the disease itself plays a role in this
association. After carefully analyzing our data, we concluded that
performing a meta-analysis was not ideal. Our main reason
behind this decision was that the type of studies included and the
extracted heterogeneous data might lead to erroneous
assumptions.
Epidemiologic, clinical, and basic science studies are needed to
investigate the association between sexual function and cIMD.
These studies should be executed in such a way that results can
be compared among different populations.
Before there is more research on this topic and to improve the
overall quality of it, agreement should be pursued on the defi-
nitions and diagnostic tools to use. Discussion on these issues
between experts from different fields such as andrology, sexology,
dermatology, and Epidemiology is needed. Such an agreement
will have a positive effect on future research projects trying to
summarize the available data (see also Table 5, research recom-
mendations to conduct future research on these topics).
Adult men consider sexual health as a highly important aspect
of quality of life,44 thus dermatologists with a commitment to
improving patient's overall health should address sexual concerns
with their patients and partners.Reproductive Hormones
In psoriasis, evidence suggests a possible association between
disease activity and abnormalities in the reproductive endocrine
axis. This is a topic where surprisingly few studies were found.
Nonetheless, these studies provide interesting information;
inflammation secondary to disease activity, via aromatase activity
stimulation, might contribute to the development of hypo-
gonadism in these men. Consequently, hypogonadism can be in
part responsible for the high prevalence of SD in this population.
The anti-inflammatory effects of testosterone have been previ-
ously described and low testosterone levels are correlated withSex Med Rev 2020;-:1e11increased expression of inflammation markers.45 Nonetheless, in
men diagnosed with cIMD, a valid estimation of the prevalence
of hypogonadism, and the influence that this has on the devel-
opment of the disease is still unknown. More research is needed
to fully understand the role of reproductive hormones on cIMD.Fertility
Sperm quality can be impaired in patients diagnosed with
psoriasis (independent of treatment), and this could be associated
with disease activity. Systemic inflammation can cause impaired
spermatogenesis by mechanisms that have not been fully eluci-
dated. For men diagnosed with psoriasis and a desire to become a
father, disease activity should be monitored before and during
the conception period. Importantly, medication is not the only
factor that can contribute to impaired fertility in men diagnosed
with psoriasis.Pregnancy and Offspring Outcomes
Considering the extensive list of diseases included in this SR,
the complete lack of studies included in this section warrants
discussion. The paternal contributions to pregnancy are vital for
a successful pregnancy. These men need to receive proper
counseling to limit the potential negative effects of disease and/or
medication on a future pregnancy. Nonetheless, currently, there
is no enough information regarding the possible influence of
paternal cIMD on pregnancy and offspring outcomes.Strengths and Limitations
Several limitations should be addressed. First, a limited
amount of studies that included a small number of participants
were identified. In addition, studies about sexual function and
fertility in men with cIMD suffer from an inconsistent meth-
odological quality mainly because a wide variety of screening
questionnaires and/or diagnostic tools were used. In conse-
quence, the definition of SD and ED was not uniformly re-
ported. Altogether, these limitations contributed to
heterogeneous data, which we consider to be too large to perform
a meta-analysis. Finally, relevant comorbidities that can also have
a direct effect on sexual function such as depression and anxiety
were not analyzed or reported in all studies.
Although we were able to provide a summary of the available
information, we consider that the major strength of this SR is its
ability to identify a large knowledge gap in this topic. Regarding
fertility and pregnancy outcomes, the complete lack of infor-
mation available should be acknowledged and prioritized for
future research plans.CONCLUSION
Evidence suggests that male SRH can be impaired in a sig-
nificant proportion of men diagnosed with psoriasis. Nonethe-
less, for the other cIMD included in this SR, information on this
topic is scarce, and no strong conclusions can be drawn other
10 Perez-Garcia et althan more research is needed and that this is still an important
neglected topic in dermatology. Future research on this topic can
provide us with relevant scientific information that can help us
understand the role of inflammation in SRH.
We encourage dermatologists to consider male SRH in their
clinical practice. Timely detection, referral, and treatment of SD
and fertility problems can have a significant impact on the quality
of life of patients and reduce the use of costly medical care. To
achieve this, dermatologists and patients must have the oppor-
tunity and necessary tools to discuss this topic.
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